Current perspectives on biosimilars

In this work, an overview of the biosimilars market, pipeline and industry targets is discussed. Biosimilars typically have a shorter timeline for approval (8 years) compared to 12 years for innovator drugs and the development cost can be 10–20% of the innovator drug. The biosimilar pipeline is revi...

Descripción completa

Detalles Bibliográficos
Autores principales: Agbogbo, Frank K., Ecker, Dawn M., Farrand, Allison, Han, Kevin, Khoury, Antoine, Martin, Aaron, McCool, Jesse, Rasche, Ulrike, Rau, Tiffany D., Schmidt, David, Sha, Ma, Treuheit, Nicholas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Fermentation, Cell Culture and Bioengineering - Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6791907/
https://www.ncbi.nlm.nih.gov/pubmed/31317293
http://dx.doi.org/10.1007/s10295-019-02216-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6791907/
https://www.ncbi.nlm.nih.gov/pubmed/31317293
http://dx.doi.org/10.1007/s10295-019-02216-z

Ejemplares similares